da Vinci vs. Hugo vs. Ottava: a practical guide

For nearly two decades, choosing a soft-tissue surgical robot meant choosing da Vinci. That changed this week. With Johnson & Johnson's Ottava securing FDA authorization on July 22 and Medtronic's Hugo already expanding beyond its initial urology clearance, hospitals now have three genuinely different systems to weigh, not just three brand names on the same basic design. Here's what actually separates them.

da Vinci 5: the incumbent, now with a sense of touch

Intuitive's newest platform is the one every challenger gets measured against, and for good reason: it carries the weight of roughly 20 million procedures behind it. The headline addition in da Vinci 5 is Force Feedback, technology that lets a surgeon feel the push and pull their instruments exert on tissue rather than relying on visual cues alone. In preclinical trials, surgeons using it applied up to 43% less force on tissue, a meaningful number for anyone who has read our piece on why haptics matter. Intuitive has since layered software on top: a Force Gauge that displays real-time tissue pressure during a case, and in-console video replay so a surgeon can review a key moment without lifting their head from the console.

The system also brings roughly ten times the computing power of earlier da Vinci models, positioning it as the foundation for the AI-driven insights Intuitive outlined in its five-layer framework at this week's SRS conference. da Vinci 5 has cleared cardiac use in the US and holds a CE mark in Europe, with more than 1,400 systems installed and over 380,000 procedures completed on the platform to date.

Hugo: the modular challenger

Medtronic's answer isn't trying to out-spec da Vinci feature for feature. It's built around a different bet: flexibility over density. The Hugo system uses independent, portable robotic arm carts rather than a single fixed unit, so a hospital can run a case with one, three, or four arms depending on what the procedure actually needs, and physically move arms between operating rooms to maximize utilization. An open console design keeps the surgeon visually connected to the bedside team, a deliberate departure from the closed, immersive consoles both competitors otherwise favor.

Hugo received FDA clearance for urologic procedures in December 2025 and has since moved to expand into general and gynecologic surgery. Outside the US, it's already been used in tens of thousands of procedures across more than 35 countries. Its most direct connection to the rest of this publication's coverage is the Touch Surgery ecosystem running underneath it, the same platform now powering Medtronic's real-time AI applications like Instrument Exit Point.

Ottava: built into the table

Ottava takes the most architecturally different approach of the three. Instead of a separate cart or boom holding the robotic arms, Ottava integrates four arms directly into a standard-sized surgical table, stowing them beneath it when not in use. Johnson & Johnson says this cuts the system's OR footprint by 30 to 50% compared to boom- and cart-mounted platforms, and enables synchronized movement between the table and the arms, so a patient can be repositioned mid-procedure without the manual adjustments other systems require.

Ottava received FDA De Novo authorization on July 22, 2026, its first US market clearance, covering general surgery procedures in the upper abdomen: gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve, and hernia repair among them. It's the newest system of the three by a wide margin, and Johnson & Johnson is launching it with a limited set of hospitals while pursuing additional clearances, so real-world procedure volume is still a fraction of what da Vinci or even Hugo has behind it.

The actual decision points

Strip away the marketing language and three questions do most of the work.

How much clinical history does the hospital need behind a platform before adopting it? da Vinci has the deepest track record by a wide margin. Ottava has almost none yet outside its pivotal trials.

Does OR space or scheduling flexibility matter more than raw capability? Hugo's modular arms and Ottava's table-integrated footprint both solve a space problem da Vinci's more traditional cart-based design doesn't prioritize.

What specialty is the procedure in? Right now, that alone narrows the field. da Vinci covers the broadest range, including cardiac. Hugo is urology-first with general and gynecologic surgery following. Ottava launches in general surgery, specifically upper-abdominal procedures.

None of these systems is close to operating without a surgeon at the console. All three are level 0 to 1 on the autonomy ladder: the surgeon initiates every motion. What's actually competing here isn't autonomy; it's ergonomics, footprint, sensory feedback, and how well each platform's software layer will support the real-time AI applications now arriving on top of all three.

Part of NextInSurgery's ongoing coverage of surgical AI. See also: Robotic Surgery Explained, Haptic Feedback in Robotic Surgery, and The Surgical AI Autonomy Ladder.